Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment
January 13, 2025 09:00 ET
|
NeuroSigma, Inc.
ATTENS (ADHD trial of external trigeminal nerve stimulation) Project, led by Professor Katya Rubia at the Institute of Psychiatry, Psychology & Neuroscience is a multicentre, double-blind,...
Final Study Completed for Cingulate’s Lead Asset CTx-1301
January 07, 2025 07:30 ET
|
Cingulate Inc.
No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025 KANSAS CITY, Kan., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000
December 23, 2024 07:30 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark’s Center for Evidence-Based Psychiatry
December 11, 2024 09:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced today that the Center for Evidence-Based Psychiatry (CEBP) in Denmark has...
ADHD: What You Need to Know
November 19, 2024 10:00 ET
|
Brain & Behavior Research Foundation
New York, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Attention-Deficit Hyperactivity Disorder (ADHD) is one of the most common mental health disorders of childhood. On Wednesday, December 4, 2024, at 7 p.m....
Annual International Conference on ADHD Hosted by CHADD, ADDA and ACO Provides Trusted Information, Guidance and Support to the ADHD Community
November 07, 2024 08:00 ET
|
Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD)
The Annual International Conference on ADHD 2024, hosted by CHADD, ADDA and ACO, will be held November 14 through 16 in Anaheim, California.
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
November 07, 2024 07:30 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy
October 29, 2024 07:48 ET
|
Praxis Bioresearch, Inc.
LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for...
October is ADHD Awareness Month
October 25, 2024 08:00 ET
|
Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD)
October is ADHD Awareness Month, and CHADD is shining a spotlight on the critical importance of accurate diagnosis and effective treatment.
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
October 08, 2024 15:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed...